Methotrexate vs Mycophenolate Mofetil for Amyopathic Dermatomyositis

Initial Treatment Algorithm

The American College of Rheumatology recommends starting with hydroxychloroquine 200 mg twice daily as first-line monotherapy for cutaneous manifestations without muscle weakness, combined with rigorous sun protection using SPF 50+ sunscreen and physical barriers 1
Evaluate treatment response at 12 weeks to determine if escalation is needed, and if hydroxychloroquine fails, escalate to combination therapy with oral prednisone 0.5-1 mg/kg/day plus methotrexate 15-20 mg/m² weekly 1, 2

Methotrexate has stronger evidence as the first-line steroid-sparing agent based on multinational guidelines and multiple clinical studies, with a guideline-level recommendation for use in juvenile dermatomyositis as a steroid-sparing agent, showing significantly earlier prednisone discontinuation and lower cumulative steroid doses 3, 4, 5
The well-established dosing regimen for methotrexate is to start at 15 mg/m² orally once weekly with 1 mg/day folic acid supplementation (or at least 5 mg folic acid per week) 6, 2
Methotrexate has a long-term safety profile that is acceptable for prolonged use 6

Mycophenolate mofetil (MMF) should be used as a second-line agent for patients who fail methotrexate or as a first-line alternative specifically for severe dermatomyositis skin disease, with a starting dose of 500 mg twice daily, which can be titrated up to 1000-1500 mg twice daily as needed 1, 2
MMF is particularly effective for severe cutaneous manifestations that are recalcitrant to other therapies, and clinical improvement typically occurs within 4-8 weeks, though full efficacy may take 3-6 months 2

For methotrexate, baseline monitoring should include AST, ALT, albumin, CBC, creatinine, chest x-ray, and consideration of hepatitis B/C serology, with ongoing monitoring of ALT/AST, creatinine, and CBC every 1-1.5 months until stable dose, then every 1-3 months 6
For MMF, monitor CBC and liver function tests regularly to detect leukopenia or transaminitis, and watch for gastrointestinal side effects (nausea, loose stools), which are the most common adverse effects 2

For methotrexate, once clinical improvement is achieved, maintain for at least 12 months before tapering to ensure prolonged remission off medication 7
For MMF, the treatment can be continued indefinitely as long as disease control is maintained, and consider withdrawal only after achieving remission for a minimum of 1 year off corticosteroids 2